bioRxiv Science⌕ Search

Biology subjects

Hoff, A.

Publications and source records attributed to Hoff, A..

2 recordsLinked to original sources

Appearance of Amyloid-β Early in Life Initiates Neuronal Hyper-excitability, Mitochondrial Decay, and Loss of Dendritic Complexity in the Hippocampal CA1 Region of 5xFAD Mice

Alzheimers disease (AD) is characterized by progressive cognitive decline and stereotyped neuropathology, yet the earliest cellular events that precede overt plaque burden and measurable behavioral impairment remain incompletely defined. Here, we tested the hypothesis that synaptic hyperexcitability and subcellular metabolic dysfunction emerge early in the 5xFAD mouse model and contribute to region-specific neuronal vulnerability before substantial amyloid plaque deposition. Using the 5xFAD heterozygous mouse, we first established the onset of transgene expression and the timing of plaque accumulation. Robust transgene expression was detected by postnatal day 15 and significant plaque accumulation by 4 months of age. Ex vivo electrophysiology revealed an early hyperexcitable phenotype at 1 month of age, including both increased AMPA receptor-mediated transmission and N-methyl-D-aspartate receptor signaling associated with the GluN2B subunit. Given the tight coupling between glutamatergic hyperactivity, calcium dysregulation, and mitochondrial health, we assessed mitochondrial structure and function at this pre-plaque stage. Mitochondrial abnormalities consistent with impaired bioenergetic homeostasis were evident. Morphological analyses further demonstrated that these early changes were associated with altered dendritic architecture in the CA1 and dentate gyrus regions, revealing hippocampal subregional susceptibility. Finally, spatial transcriptomics supported this anatomical selectivity by identifying regionally enriched molecular signatures consistent with differential vulnerability. The CA1 region exhibited more reductions in mitochondria-related transcripts than CA3 or dentate gyrus and these reductions were specifically associated with CA1 pyramidal cell neurons. Together, these findings define a pre-plaque window in 5xFAD mice marked by GluN2B-linked glutamatergic hyperexcitability, early mitochondrial disruption, and selective dendritic and transcriptional vulnerability across hippocampal subregions. This integrated timeline suggests that synaptic and metabolic dysfunctions arise before substantial plaque deposition and may represent tractable early targets for intervention aimed at delaying or preventing downstream neurodegeneration in AD.

neuroscience↗

Lipotoxicity Induces Beta Cell Small Extracellular Vesicle-mediated Beta Cell Dysfunction

Chronically elevated circulating excess free fatty acids (i.e. lipotoxicity) is a pathological process implicated in several metabolic disorders, including obesity-driven Type 2 diabetes (T2D). Lipotoxicity exerts detrimental effects on pancreatic islet {beta}-cells by reducing glucose-stimulated insulin secretion (GSIS), altering {beta}-cell transcriptional identity, and promoting apoptosis. While {beta}-cell-derived small extracellular vesicles (sEV) have been shown to contribute to {beta}-cell failure in T2D, their specific role in lipotoxicity-mediated {beta}-cell failure remains to be elucidated. In this work, we demonstrate that lipotoxicity enhances the release of sEVs from {beta}-cells, which exhibit altered proteomic and lipidomic profiles. These lipotoxic sEV induce {beta}-cell dysfunction in healthy mouse and human islets and trigger significant islet transcriptional changes, including the upregulation of genes associated with the TGF{beta}/Smad3 pathway, as noted by RNA sequencing. Importantly, pharmacological inhibition of the TGF{beta}I/II receptor improved lipotoxic sEV-induced {beta}-cell dysfunction, underscoring their involvement in activating the TGF{beta}/Smad3 pathway during this process. We have comprehensively characterized lipotoxic {beta}-cell sEVs and implicated their role in inducing {beta}-cell functional failure in T2D. These findings highlight potential avenues for therapeutic interventions targeting sEV-mediated pathways to preserve {beta}-cell health in metabolic disorders. Article HighlightsO_LIDiabetogenic lipotoxic conditions enhance {beta}-cell sEV release and induce alterations in both protein and lipid content. C_LIO_LIGlobal islet transcriptional changes and alterations in {beta}-cell function were noted upon exposure to lipotoxic sEV. C_LIO_LILipotoxic sEV were shown to activate the TGF{beta}/Smad3 pathway and blockade of this pathway improved {beta}-cell function. C_LI

molecular biology↗